Evidence map›Paper›PMID 40937249›Full record

ArticleCureus2025

Isolated Rapidly Progressive Interstitial Lung Disease Without Muscle or Skin Involvement in Idiopathic Inflammatory Myopathy: An Unusual Anti-Mi-2 Antibody Phenotype.

Rajesh Kumar, Sushil Kumar, Ruthra Kumaran, Chandan Kumar, Kanchan K Kujur

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rajesh KumarInternal Medicine and Rheumatological Services, All India Institute of Medical Sciences Deoghar, Deoghar, IND.
Sushil KumarGeneral Medicine, All India Institute of Medical Sciences Deoghar, Deoghar, IND.
Ruthra KumaranInternal Medicine, All India Institute of Medical Sciences Deoghar, Deoghar, IND.
Chandan KumarInternal Medicine, All India Institute of Medical Sciences Deoghar, Deoghar, IND.
Kanchan K KujurInternal Medicine, All India Institute of Medical Sciences Deoghar, Deoghar, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-Mi-2 antibodies are myositis-specific autoantibodies typically associated with cutaneous manifestations in idiopathic inflammatory myositis with favourable outcomes. Interstitial lung disease (ILD), particularly rapidly progressive ILD (RP-ILD), is rarely linked to anti-Mi-2 and even more infrequently presents without muscle or skin involvement. We report a rare case of a 58-year-old male patient presenting with isolated RP-ILD without cutaneous or muscular manifestations. Laboratory evaluation revealed normal muscle enzymes and negative autoimmune markers, with myositis profile revealing isolated anti-Mi-2β antibody positivity, confirmed by enzyme-linked immunosorbent assay (ELISA) and immunoblot. Radiological features on high-resolution CT, coupled with the rapidity of progression, were suggestive of RP-ILD. Despite initial improvement with pulse corticosteroids and cyclophosphamide, the patient discontinued treatment and succumbed to the illness within two months. This case highlights an extremely rare anti-Mi-2 phenotype presenting solely with RP-ILD. Although anti-Mi-2 is typically linked to benign clinical courses, this case underscores its potential association with severe pulmonary manifestations in the absence of classic dermatomyositis features. Clinicians should be aware of atypical anti-Mi-2 presentations, including isolated RP-ILD. Early recognition and aggressive immunosuppressive therapy are critical to improving outcomes. Further research is essential to understand the underlying mechanisms and optimal management strategies in such presentations.

Indexed as

amyopathic dermatomyositisanti-mi-2idiopathic inflammatory myopathyild without myositisrapidly progressive interstitial lung disease

Identifiers

PMID40937249
PMCPMC12421932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.